These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy. Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884 [TBL] [Abstract][Full Text] [Related]
3. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy. Walton ZE; Frigault MJ; Maus MV Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525 [TBL] [Abstract][Full Text] [Related]
4. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy. Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616 [TBL] [Abstract][Full Text] [Related]
5. EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study. Korell F; Penack O; Mattie M; Schreck N; Benner A; Krzykalla J; Wang Z; Schmitt M; Bullinger L; Müller-Tidow C; Dreger P; Luft T Front Immunol; 2022; 13():877477. PubMed ID: 35464403 [TBL] [Abstract][Full Text] [Related]
6. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Kotch C; Barrett D; Teachey DT Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357 [No Abstract] [Full Text] [Related]
7. Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study. Caballero-Bellón M; Alonso-Saladrigues A; Bobillo-Perez S; Faura A; Arqués L; Rivera C; Català A; Dapena JL; Rives S; Jordan I Front Immunol; 2023; 14():1219289. PubMed ID: 37600775 [TBL] [Abstract][Full Text] [Related]
8. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Hughes AD; Teachey DT; Diorio C Semin Immunopathol; 2024 Jul; 46(3-4):5. PubMed ID: 39012374 [TBL] [Abstract][Full Text] [Related]
9. Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy. Ann Hematol; ; . PubMed ID: 38214708 [TBL] [Abstract][Full Text] [Related]